CABA Cabaletta Bio
Price Chart
Executive Summary
Cabaletta Bio reported Q4 and full-year 2025 financial results, highlighted by increased R&D spending and a cash position of $133.6 million, sufficient to fund operations into Q4 2026. The company reiterated key clinical milestones for rese-cel, including complete Phase 1/2 data readouts in 1H26 and a planned BLA submission for myositis in 2027.
Key Financial Metrics
Actionable Insight
Monitor upcoming Phase 1/2 data readouts in 1H26, particularly from RESET-SLE and RESET-SSc, which could inform registrational pathways and potentially catalyze investor interest despite lack of near-term revenue.
Key Facts
- R&D expenses increased to $36.2M (Q4 2025) from $25.5M (Q4 2024); full-year R&D rose to $142.7M from $97.2M.
- G&A expenses decreased to $6.4M (Q4 2025) from $8.3M (Q4 2024).
- Cash, cash equivalents, and short-term investments totaled $133.6M as of December 31, 2025, down from $164.0M a year prior.
- Company raised an additional $30.0M in Q1 2026 via ATM sales and warrant exercises.
- Cash runway expected through Q4 2026.
- Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG trials expected in 1H26.
- BLA submission for rese-cel in myositis anticipated in 2027 based on 17-patient registrational cohort.
Financial Impact
Increased R&D spend by $45.5M year-over-year; net loss widened to $167.9M in 2025 from $115.9M in 2024.
Risk Factors
- High cash burn with no approved products; dependent on successful clinical outcomes and future financing.
- Clinical timelines are forward-looking and subject to delays; no guarantee that data will support BLA submission or approval.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260280 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $3.00 awaiting T+1 | awaiting T+1 | — | $3.01 (+0.33%) |
|
Jun 3, 2026
10d ago
|
8-K
| $3.58 $3.51 | ▼ −1.96% | ▼ −2.35% | $3.01 (−15.92%) |
|
Jun 1, 2026
12d ago
|
DEFA14A
| $3.67 $3.68 | ▲ +0.27% | ▲ +0.13% | $3.01 (−17.98%) |
|
May 14, 2026
4w ago
|
8-K
| $3.61 $3.31 | ▲ +8.31% | ▲ +7.08% | $3.01 (+16.62%) |
|
May 14, 2026
4w ago
|
Press Release
| $3.61 $3.31 | ▼ −8.31% | ▼ −7.08% | $3.01 (−16.62%) |
|
May 14, 2026
4w ago
|
8-K
| $3.61 $3.31 | ▼ −8.31% | ▼ −7.08% | $3.01 (−16.62%) |
|
May 4, 2026
5w ago
|
8-K
| $3.83 $4.15 | ▼ −8.36% | ▼ −7.56% | $3.01 (+21.41%) |
|
May 4, 2026
5w ago
|
424B5
| $3.83 $4.15 | ▼ −8.36% | ▼ −7.56% | $3.01 (+21.41%) |
|
May 4, 2026
5w ago
|
8-K
| $3.83 $4.15 | ▲ +8.36% | ▲ +7.56% | $3.01 (−21.41%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $2.86 $2.78 | ▼ −2.80% | ▼ −2.79% | $3.01 (+5.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access